SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don Miller who wrote (3783)10/21/1999 1:17:00 PM
From: Biomaven  Read Replies (4) of 10280
 
Southwell presented at the Mass Biotech conference earlier this week. Not much new, but a few snippets:

Expects 1 more significant deal before year-end. Mentioned Zopiclone and oxybutinin ICE as generating significant partnering interest. May ask for a "quid" for their sales force to sell.

Mentioned that Zopiclone has quicker onset and longer half-life than competitors.

Seemed a little downbeat on Xopenex, although did say new scrips were now picking up nicely. Confirmed the Quintiles detailing. Price is 4x generic.

Thinks formoterol ICE will ultimately be bigger drug than Xopenex because no generic competition.

Confirmed Zyrtec European royalty as 5% rising to 12%.

Lilly is charging ahead full bore on Prozac II studies in both depression and anxiety - 6 Phase IIA studies and several thousand patients - might even be able to skip Phase III because studies are so large. NDA expected 2001, for launch in 2002. FTC response could be this year or up to 9 months away.

Sibutramine ICE IND will be early next year - this seems to have slipped a little. Multiple indications.

Propulsid - J&J focusing on IBD and reflux.

Interesting new NCE - a pre-clinical morphine-strength pain drug with no respiratory depression.

Have looked at acquisitions, but haven't seen anything they liked enough.

BTW, the slides he used are available at SEPR's web site. He spoke rapidly, and so there could well be some inaccuracies in what I reported above.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News